Long-Read Full-Length Complementary Deoxyribonucleic Acid (CDNA) Sequencing Global Market Report 2026

The long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing market size has grown rapidly in recent years. It will grow from $1.34 billion in 2025 to $1.59 billion in 2026 at a compound annual growth rate (CAGR) of 18.6%. The growth in the historic period can be attributed to advancements in long-read sequencing technologies, increasing research in transcriptome analysis, rising funding for genomics research, growing adoption of pacbio and nanopore platforms, expanding applications in gene expression studies.

The long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing market size is expected to see rapid growth in the next few years. It will grow to $3.18 billion in 2030 at a compound annual growth rate (CAGR) of 18.9%. The growth in the forecast period can be attributed to growing demand for precision medicine applications, increasing integration of AI-driven bioinformatics tools, rising use in rare disease research, expansion of clinical transcriptomics, development of cost-efficient long-read sequencing workflows. Major trends in the forecast period include increasing adoption of single-cell full-length cDNA sequencing, rising demand for high-fidelity long-read platforms, growing use in alternative splicing detection, expansion of transcript isoform characterization studies, rising integration of advanced library preparation kits.

The increasing emphasis on precision medicine is anticipated to drive the growth of the long-read full-length cDNA sequencing market in the coming years. Precision medicine is a healthcare approach that tailors prevention and treatment based on an individual’s genetic and molecular profile. The emphasis on precision medicine is rising due to the growing demand for effective treatments for heterogeneous and therapy-resistant diseases. Long-read full-length cDNA sequencing improves clinical decision-making by delivering detailed insights into transcript isoforms and actionable biomarkers, thereby enabling more accurate selection of targeted therapies. For instance, in February 2024, according to the Personalized Medicine Coalition, a United States-based non-profit organization, in 2023, the U.S. Food and Drug Administration (FDA) authorized 16 new personalized therapies for patients with rare diseases, representing a significant increase from the six approvals reported in 2022. Therefore, the increasing emphasis on precision medicine is fueling the growth of the long-read full-length cDNA sequencing market.

Leading companies operating in the long-read full-length cDNA sequencing market are concentrating on developing advanced solutions, such as high-fidelity single-molecule sequencing platforms, to enhance transcript accuracy and identify complex RNA isoforms. High-fidelity single-molecule sequencing platforms, which read complete cDNA molecules with minimal error rates without requiring fragmentation, enable precise capture of full-length transcripts and identification of complex RNA isoforms within a single run. For example, in December 2023, Pacific Biosciences of California Inc., a United States-based biotechnology company, introduced Kinnex RNA kits aimed at advancing RNA research capabilities. It utilizes high-fidelity single-molecule sequencing platform technology integrated with optimized library preparation workflows to generate highly accurate, long-read transcriptome data. Its distinctive features include ultra-long reads covering entire transcripts, high consensus accuracy, and compatibility with complex RNA samples, allowing researchers to identify alternative splicing events, fusion transcripts, and novel isoforms with exceptional precision. Kinnex has applications in genomics, transcriptomics, biomarker discovery, and therapeutic target identification, providing a more detailed and comprehensive understanding of RNA biology compared to traditional methods.

In February 2026, ArgenTag, a US-based biotechnology company based in the United States, entered into a partnership with Pacific Biosciences of California Inc. (PacBio) to enhance long-read single-cell transcriptomics capabilities. Through this collaboration, Argenta Genomics Inc. and Pacific Biosciences of California, Inc. intend to combine PacBio’s highly precise long-read sequencing platforms with Argenta’s single-cell analysis techniques to facilitate deeper and more detailed profiling of cellular transcriptomes, thereby strengthening the discovery and characterization of complex biological mechanisms. Pacific Biosciences, Inc. is a US-based organization that focuses on long-read DNA sequencing technology for genomics research and clinical applications.

Major companies operating in the long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing market are Eurofins Scientific SE, Bio-Rad Laboratories Inc., QIAGEN N.V., 10x Genomics Inc., Azenta Life Sciences Inc., BGI Genomics Co. Ltd., Novogene Co. Ltd., Takara Bio Inc., Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., New England Biolabs Inc., Macrogen Inc., DNAnexus Inc., Zymo Research Corporation, CD Genomics Inc., BaseClear B.V., Microsynth AG, Creative Biogene Inc., Nucleome Informatics Inc., Operify Tech Pvt. Ltd., Signios Bio Inc.

North America was the largest region in the long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The long-read full-length complementary DNA (cDNA) sequencing market consists of revenues earned by entities by providing services such as full-length transcript sequencing, isoform identification, alternative splicing analysis, gene expression profiling, and RNA modification detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The long-read full-length cDNA sequencing market also includes sales of RNA extraction kits, quality control tools, and specialized reagents, and nucleic acid quantification kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Long-read full-length complementary DNA (cDNA) sequencing is a method that captures and sequences entire complementary DNA (cDNA) molecules generated from RNA transcripts, maintaining their complete full-length structure. It offers a detailed and comprehensive view of transcriptomes, enabling accurate characterization of complex RNA molecules.

The primary technologies of long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing include Pacific Biosciences single-molecule real-time (PacBio SMRT), Oxford Nanopore, and other related technologies. Pacific Biosciences single-molecule real-time (PacBio SMRT) is a sequencing technology that enables highly precise, long-read sequencing of full-length cDNA molecules to support comprehensive transcriptome analysis. The product types include instruments and sequencing platforms, reagents and consumables, library preparation kits, flow cells and chips, and data analysis software and bioinformatics tools, and the sample types include human, animal, plant, and microbial samples. These technologies are applied in transcriptome analysis, gene expression studies, alternative splicing detection, fusion gene detection, and other applications, serving end users such as academic and research institutes, pharmaceutical and biotechnology companies, clinical laboratories, and other end users.

Tariffs on imported sequencing instruments, flow cells, and reagents are impacting the long-read full-length cDNA sequencing market by increasing equipment and consumable costs, particularly affecting instruments and sequencing platforms and reagents and consumables segments. Regions such as North America, Europe, and Asia-Pacific that rely heavily on cross-border supply chains for advanced genomics equipment are most affected. Academic institutes and pharmaceutical and biotechnology companies face higher procurement costs, especially for premium platforms. However, tariffs are also encouraging regional manufacturing of sequencing consumables, fostering local innovation, and strengthening domestic supply chain resilience.

The long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing market research report is one of a series of new reports that provides long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing market statistics, including long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing industry global market size, regional shares, competitors with a long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing market share, detailed long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing industry. This long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.